187 related articles for article (PubMed ID: 16156659)
1. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.
Dimitrov AS; Louis JM; Bewley CA; Clore GM; Blumenthal R
Biochemistry; 2005 Sep; 44(37):12471-9. PubMed ID: 16156659
[TBL] [Abstract][Full Text] [Related]
2. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
3. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
[TBL] [Abstract][Full Text] [Related]
4. Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.
Gallo SA; Reeves JD; Garg H; Foley B; Doms RW; Blumenthal R
Retrovirology; 2006 Dec; 3():90. PubMed ID: 17144914
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
Gustchina E; Louis JM; Bewley CA; Clore GM
J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381
[TBL] [Abstract][Full Text] [Related]
6. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB; Egelhofer M; von Laer D
J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
[TBL] [Abstract][Full Text] [Related]
7. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors.
Li J; Chen X; Huang J; Jiang S; Chen YH
Immunobiology; 2009; 214(1):51-60. PubMed ID: 19159827
[TBL] [Abstract][Full Text] [Related]
8. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.
Follis KE; Larson SJ; Lu M; Nunberg JH
J Virol; 2002 Jul; 76(14):7356-62. PubMed ID: 12072535
[TBL] [Abstract][Full Text] [Related]
9. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.
Jiang S; Lin K; Lu M
J Virol; 1998 Dec; 72(12):10213-7. PubMed ID: 9811763
[TBL] [Abstract][Full Text] [Related]
10. Efficient Fusion at Neutral pH by Human Immunodeficiency Virus gp41 Trimers Containing the Fusion Peptide and Transmembrane Domains.
Liang S; Ratnayake PU; Keinath C; Jia L; Wolfe R; Ranaweera A; Weliky DP
Biochemistry; 2018 Feb; 57(7):1219-1235. PubMed ID: 29345922
[TBL] [Abstract][Full Text] [Related]
11. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
[TBL] [Abstract][Full Text] [Related]
12. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
Maerz AL; Drummer HE; Wilson KA; Poumbourios P
J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331
[TBL] [Abstract][Full Text] [Related]
14. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.
Frey G; Rits-Volloch S; Zhang XQ; Schooley RT; Chen B; Harrison SC
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):13938-43. PubMed ID: 16963566
[TBL] [Abstract][Full Text] [Related]
15. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.
Bewley CA; Louis JM; Ghirlando R; Clore GM
J Biol Chem; 2002 Apr; 277(16):14238-45. PubMed ID: 11859089
[TBL] [Abstract][Full Text] [Related]
16. Identification of the HIV-1 gp41 core-binding motif--HXXNPF.
Huang JH; Liu ZQ; Liu S; Jiang S; Chen YH
FEBS Lett; 2006 Sep; 580(20):4807-14. PubMed ID: 16904109
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
18. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
19. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide.
Noah E; Biron Z; Naider F; Arshava B; Anglister J
Biochemistry; 2008 Jul; 47(26):6782-92. PubMed ID: 18540633
[TBL] [Abstract][Full Text] [Related]
20. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
Liu S; Jiang S
Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
